SCHEMBL22409635

SCHEMBL22409635

CCC1(C)OC(=O)C(=CC=Cc2csc3ccccc23)C(=O)O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ KDM4C Q9H3R0 1/20 0.42
▸ CYP2A6 P11509 1/20 0.41
▸ MAPK1 P28482 2/20 0.39
▸ MAOB P27338 1/20 0.39
▸ PTGS1 P23219 1/20 0.38
▸ PTGS2 P35354 1/20 0.38
▸ AHR P35869 1/20 0.37
▸ TUBB4A P04350 1/20 0.37
▸ TUBB P07437 1/20 0.37
▸ TUBA3C P0DPH7 1/20 0.37
▸ TUBA1B P68363 1/20 0.37
▸ TUBA4A P68366 1/20 0.37
▸ TUBB4B P68371 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22409622 0.89 ALDH1A1 (0.47) MAPTMEN1KMT2AALDH1A1TDP1
SCHEMBL22409595 0.79 MTNR1A (0.38) MAPTMEN1KMT2AKDM4EMAPK1
SCHEMBL22409638 0.75 AURKA (0.39) MAPTMEN1KMT2AMAPK1POLB
SCHEMBL22409630 0.75 MAPT (0.41) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL22423745 0.75 MAPT (0.41) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL22423779 0.74 NR1I2 (0.35) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL22409634 0.74 NR1I2 (0.35) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL22409632 0.71 APP (0.33) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL22409639 0.69 APP (0.45) MAPTMEN1KMT2AALDH1A1TDP1
SCHEMBL22409641 0.68 CYP2A6 (0.67) MAPTMEN1KMT2AALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof NATIONAL GUARD HEALTH AFFAIRS (SA) 2021-11-02 — — US disclosed
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF NATIONAL GUARD HEALTH AFFAIRS (SA) 2020-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof PDK1, PDHA1, PDHA2 MAPT 4235/4885MEN1 757/4885KMT2A 1048/4885
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF PDK1, PDHA1, PDHA2 MAPT 4235/4885MEN1 757/4885KMT2A 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback